La Matinale - 08-06-2023 - Portzamparc
INNATE PHARMA : IPH6101 licencié à Sanofi obtient le statut « Fast Track » – Acheter (1), obj. 8.40€ ..Cours: 2.89€ au 07/06/23PHERECYDES PHARMA : Une nouvelle indication pour les phages anti-S. aureus – Acheter (1), obj. 5.80€ Cours: 1.94€ au 07/06/23
COLLECTE / DECOLLECTE : En pente douce
Innate Pharma S.A. is a biopharmaceutical Company developing immunotherapy drugs for cancer and inflammatory diseases. Co. specializes in the development of new monoclonal antibodies targeting receptors and pathways controlling the activation of innate immunity cells. Also, Co. has three product-candidates resulting from its research platform are being tested in clinical trials; two of these by Co.'s partners, Bristol-Myers Squibb and Novo Nordisk A/S. Co. focuses on immunopharmacology and antibody technology. Co. has a panel of molecular and cellular assays and in vivo models for assessing the pharmacodynamics, the pharmacotoxicology and efficacy of drug candidates.
Portzamparc is a subsidary of BNP Paribas which adapted the mission to contribute to responsible and sustainable growth of private clients, management companies and SMEs . They offer personalized support adapted to the objectives in particular for Small and Medium-Sized Enterprises.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.